Perceptive Advisors’s Immunocore IMCR Stock Holding History

Perceptive Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-360,000	Closed	-$12.3M	–	143
2021 Q4	$12.3M	Sell	360,000 -40,000	-10%	-$1.45M	0.19%	81
2021 Q3	$14.8M	Hold	400,000	–	–	0.22%	83
2021 Q2	$15.6M	Hold	400,000	–	–	0.2%	92
2021 Q1	$17M	Buy	+400,000	New	+$17.8M	0.22%	82

Other funds holding IMCR

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Perceptive Advisors's IMCR Position: Q1 2022 in Review

Perceptive Advisors sold out of Immunocore (IMCR) in Q1 2022, closing a stake of 360,000 shares — an estimated $12.3M sold.

Perceptive Advisors first reported a position in IMCR in Q1 2021 and held it in 4 quarters. The position peaked at $17M in Q1 2021. 57 funds tracked by Wall St. Rank hold IMCR as of Q1 2022.

Perceptive Advisors reported no remaining Immunocore position as of Q1 2022 after selling out during the quarter.
Perceptive Advisors sold 360,000 Immunocore shares in Q1 2022, an estimated $12.3M.
Perceptive Advisors first reported a position in Immunocore in Q1 2021 and held it in 4 quarters.
Perceptive Advisors's Immunocore position peaked at $17M in Q1 2021.
57 funds tracked by Wall St. Rank held Immunocore as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.